Results 91 to 100 of about 624,544 (348)

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

On the Acquisition of English Voiceless Stop VOT by Indonesian-English Bilinguals: Evidence of Input Frequency

open access: yesK@ta: A Biannual Publication on the Study of Language and Literature, 2019
The paper attempts to investigate the acquisition of Voice Onset Time (VOT) of voiceless stop consonants of English /p/, /t/, and /k/ by Indonesian-English bilingual children in its close relation to how second language (L2) input shapes the L2 VOT ...
Evynurul Laily Zen
doaj   +1 more source

Larynx height during English stop consonants*

open access: yesJournal of Phonetics, 1980
Abstract Many studies argue that larynx lowering would effectively maintain the transglottal airflow necessary for voicing to continue during stop closure. The empirical support for this hypothesis is primarily the tendency of the larynx to be lower for voiced than for voiceless stops.
openaire   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

Physiological effects on stop consonant voicing [PDF]

open access: yesThe Journal of the Acoustical Society of America, 1983
Voiced and voiceless stops in initial position are known to differ in Voice Onset Time; they may also differ in closure duration and the duration of closure voicing. Besides the voicing distinction, such factors as the position of the stop in a word or utterance, the stop's place of articulation, and the stress of adjacent syllables will also affect ...
openaire   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy